1CM
DNLI icon

1492 Capital Management’s Denali Therapeutics DNLI Stock Holding History

1492 Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Sell
67,417
-70
-0.1% -$1.39K 0.49% 63
2025
Q4 		$1.11M Buy
+67,487
New +$1.14M 0.43% 64

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

1492 Capital Management's DNLI Position: Q1 2026 in Review

1492 Capital Management reduced its Denali Therapeutics (DNLI) stake by 0.1% in Q1 2026, selling an estimated $1.39K and leaving 67,417 shares worth $1.29M. The position accounts for 0.49% of the portfolio, ranked #63.

1492 Capital Management first reported a position in DNLI in Q4 2025 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • 1492 Capital Management held 67,417 shares of Denali Therapeutics worth $1.29M as of Q1 2026.
  • 1492 Capital Management sold 70 Denali Therapeutics shares in Q1 2026, an estimated $1.39K.
  • Denali Therapeutics made up 0.49% of 1492 Capital Management's portfolio in Q1 2026, its #63 holding.
  • 1492 Capital Management first reported a position in Denali Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.